ReviewDrugs2006
Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- A Systematic Review of Risk Factors for Suicide Among Persons Living with HIV (1996-2020).AIDS and behavior · 2022Pooled it
- Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Pooled it
- Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Trial
- A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.The American journal of gastroenterology · 2011Trial
- Trial
- Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.The American journal on addictionsTrial
- An epidemiological study of hepatitis virus infection in psychiatric patients in East China.BMC public health · 2025Article
- Patient-oriented unsupervised learning to uncover the patterns of multimorbidity associated with stroke using primary care electronic health records.BMC primary care · 2024Article
- Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Differences by sex in associations between injection drug risks and drug crime conviction among people who inject drugs in Almaty, Kazakhstan.The International journal on drug policy · 2018Article
- Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment.World journal of hepatology · 2016Article
- Hepatitis C virus as a systemic disease: reaching beyond the liver.Hepatology international · 2016Review
- Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.World journal of hepatology · 2015Review
- Denial of prescription analgesia among people who inject drugs in a Canadian setting.Drug and alcohol review · 2015Observational
- Commentary: Methamphetamine mediates immune dysregulation in a murine model of chronic viral infection.Frontiers in microbiology · 2015Article
- Neurologic manifestations of acute and chronic liver disease.Continuum (Minneapolis, Minn.) · 2014Review
- Neuroimmune basis of methamphetamine toxicity.International review of neurobiology · 2014Review
- Acceptability of psychotherapy, pharmacotherapy, and self-directed therapies in Australians living with chronic hepatitis C.Journal of clinical psychology in medical settings · 2013Article
- Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.Digestive diseases and sciences · 2013Article
- Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.Pharmacology & therapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is a major health concern in the US as well as in other countries worldwide. Treatment issues and disease management strategies are complicated by the extremely high rate of psychiatric and substance use disorders in those who have HCV. The majority of new and existing cases of HCV are related to injection drug use and, in this population, the prevalence of psychiatric comorbidity is high. Optimally, all patients with HCV should be screened for psychiatric and substance use disorders before initiation of antiviral therapy. If a patient screens positive, he or she should be referred to a mental healthcare provider or addiction specialist, assessed for the presence of a psychiatric or substance use disorder, and appropriately treated prior to initiation of antiviral (i.e. interferon) therapy. Although interferon-based therapies can lead to severe neuropsychiatric adverse effects, including in rare instances suicide, evidence suggests that many patients with comorbid psychiatric and substance use diagnoses can be treated safely and effectively using comanagement strategies. However, most patients with HCV are not treated with antiviral therapy. Therefore, we must expand our definition of HCV 'treatment' to include treatment of the comorbid psychiatric and substance use disorders that accompany HCV infection and precede antiviral therapy. This paper reviews the epidemiology and management of psychiatric and substance use disorders in patients with HCV, the issue of psychiatric and substance use disorders as contraindications for antiviral therapy, and current treatment strategies for HCV patients with these comorbid conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.